The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.

① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.

cls.cnJan 5 19:05 ET

The number has reached a historical high! So far this year, 17 A-share listed companies have announced special dividend plans, including Contemporary Amperex Technology and Yunnan Baiyao Group.

① According to incomplete Statistics, as of the time of publication, 17 A-share listed companies have announced special dividend plans for 2024 this year (attached table), setting a record high for the year. Among them, the special dividend amounts of Contemporary Amperex Technology, Yunnan Baiyao Group, S.F. Holding, and others exceed 2 billion yuan. ② In addition, listed companies such as Fuhua, Three Squirrels Inc., and Chongqing Qin'an M&E PLC have announced special dividend plans before the Spring Festival.

cls.cnDec 28, 2024 02:00 ET

It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17, 2024 09:51 ET

henan lingrui pharmaceutical plans to acquire Silver Valley Pharmaceuticals for 0.782 billion. Traditional Chinese medicine patch and plaster leading the cross-border pharmaceutical market | Quick reading announcement

①Henan Lingrui Pharmaceutical intends to acquire all the equity of Silver Valley Pharmaceutical for 0.782 billion yuan, entering the market of innovative drugs in chemical medicine. ②According to Mononucleosis Medical Data, Silver Valley Pharmaceutical's sales in 2023 exceeded 0.4 billion yuan, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of Class 1 new drug Biti Cong quickly. ③If the acquisition of Silver Valley Pharmaceutical proceeds smoothly, the company's previously set stock-based incentive unlocking target may be difficult to achieve or significantly reduced.

cls.cnDec 4, 2024 10:07 ET

beijing tongrentang channel research: the high-end series has started to layout, there are still "gaps" in the out-of-hospital channels, and mergers and acquisitions have taken root in the in-hospital market | company research

① This Friday, the chairman of beijing tongrentang, Di Shubing, officially assumes the role of general manager of beijing tongrentang Group. ② The high-end imperial medicine series is primarily sold in beijing tongrentang pharmacies and remains hard to find in some city chain pharmacies. The company stated that the overall sales situation is in line with expectations. ③ beijing tongrentang Commercial Company acquired 51% of Honghui Medical for 0.105 billion, exploring the medical market, but there are still gaps in the outpatient medium and large chain market.

cls.cnNov 30, 2024 09:42 ET